Stephen A Donahue

US Patent:

20100204286, Aug 12, 2010

Filed:

Feb 11, 2010

Appl. No.:

12/704286

Inventors:

Stephen R. Donahue - Lexington MA, US
John J. Byrnes - Ashland MA, US

International Classification:

A61K 31/426
A61K 31/4172
A61K 31/415
A61P 35/00
A61P 1/00

US Classification:

514365, 514400, 514406

Abstract:

A method for moderating a gastrointestinal adverse effect induced by at least one cytotoxic agent, for example ionizing radiation and/or at least one chemotherapeutic agent, in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), pharmaceutically acceptable salts thereof and prodrugs thereof. A method for treating a cancerous condition in a subject comprises administering to the subject (a) at least one cytotoxic anticancer agent, for example ionizing radiation and/or at least one chemotherapeutic agent; and (b) an ACE2 inhibitor or a compound selected from ORE1001, pharmaceutically acceptable salts thereof and prodrugs thereof in an amount effective to moderate a gastrointestinal adverse effect induced by the anticancer agent.

US Patent:

20100035848, Feb 11, 2010

Filed:

Mar 10, 2009

Appl. No.:

12/401143

Inventors:

Stephen Richard Donahue - Lexington MA, US
Michael David Jacobson - Cambridge MA, US
Luz-Maria Guzman - Watertown MA, US
Thomas Michael Barnes - Brookline MA, US
Robert Mark Coopersmith - Chestnut Hill MA, US
Scott Edward Malstrom - Reading MA, US

International Classification:

A61K 31/4164
A61P 29/00
A61P 1/00
A61P 1/04
A61K 31/60
A61K 31/421
A61K 31/5415

US Classification:

514161, 514400, 514374, 5142265

Abstract:

A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated, comprises an NSAID in an anti-inflammatory, analgesic or antipyretic effective amount and a gastroprotective agent that comprises an ACE2 inhibitor in an amount effective to protect mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by the NSAID.